Dharmacon

Dharmacon, a Revvity brand, provides innovative functional genomics solutions, focusing on RNA interference and CRISPR technologies to facilitate advanced genetic research and therapeutic discovery. Founded in 1995 in Lafayette, US, Dharmacon specializes in functional genomics solutions. The company was acquired by Fisher Scientific International Inc. in February 2004 for USD 80 mn.

Co-founders Laurie Wilmot and Meghan Flaherty led the company's early initiatives in RNAi and CRISPR technologies, contributing to its growth in the scientific community. Dharmacon Reagents, as a Revvity brand, specializes in functional genomics solutions, particularly in RNA interference (RNAi) and CRISPR gene editing technologies. They offer a comprehensive range of products, including synthetic oligonucleotides, algorithm-designed small interfering RNAs (siRNAs), guide RNAs for CRISPR-Cas9 applications, and custom-designed oligonucleotides. These products support researchers in conducting a variety of experiments, including single-gene investigations and whole genome screens.

Their clientele spans academic and pharmaceutical researchers across North America, Europe, and Asia-Pacific, aiding in the exploration of complex biological networks. Dharmacon Reagents generates revenue primarily through direct sales of their product portfolio to academic institutions, biotechnology companies, and pharmaceutical firms. Researchers procure reagents and kits, leading to recurring sales for essential consumables like siRNAs and CRISPR reagents. Their pricing strategy accommodates diverse budgets, often including discounts for bulk purchases and subscription models.

Key products like the Pin-point™ Base Editing Reagents and various CRISPR libraries significantly contribute to their revenue, providing innovative tools for gene editing and functional genomics. Dharmacon is focused on expanding its product offerings and geographic presence. Plans include launching new products tailored for advanced genomic research, aligning with market needs. The company aims to penetrate emerging markets in Asia-Pacific and Europe by 2025, utilizing recent funding from their acquisition to enhance product development and marketing efforts.

The strategic acquisition by Fisher Scientific International in February 2004 for USD 80 mn supports Dharmacon's long-term growth initiatives.